Target intelligence / Profile preview

Interleukin-12 and Interleukin-23 p40 subunit (IL-12/IL-23 p40)

Target
IL-12/IL-23 p40
Molecular classification
Cytokine subunit, Cytokine receptor ligand, Immune system protein, Interleukin family
01

Overview

The **Interleukin-12 and Interleukin-23 p40 subunit** is a protein chain shared by the heterodimeric cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), both key mediators of immune and inflammatory processes[1][2][4][5]. The p40 subunit, encoded by the IL12B gene, pairs with p35 to form IL-12 and with p19 to form IL-23. Both cytokines then signal via specific cell surface receptors to promote the differentiation and maintenance of T helper cell populations—Th1 in the case of IL-12 and Th17 for IL-23. Oversupply or dysregulation of IL-12/IL-23 p40 has been strongly implicated in autoimmune diseases, chronic inflammation, and certain cancers. The unique sharing of this subunit by IL-12 and IL-23 enables targeted therapies such as monoclonal antibodies (e.g., ustekinumab) to inhibit both cytokines simultaneously and modulate immune-mediated pathology[1][2][4][5].

Other names
IL-12BIL-12 subunit betaIL-12p40p40Interleukin-12 subunit betaIL-23 p40
02

Mechanism of action

Monoclonal antibodies that bind to the p40 subunit, thereby inhibiting the activity of both interleukin-12 and interleukin-23 and their downstream immunological effects[4].

03

Biological functions

Modulation of T helper cell differentiationSignal transduction in immune responsesPromotion of Th1 (with IL-12) and Th17 (with IL-23) immune pathwaysRegulation of innate and adaptive immunityProinflammatory signaling
04

Disease associations

InflammationAutoimmune diseaseCancerInfection
05

Safety considerations

Increased infection risk with therapy (due to immunosuppression)Potential increased cancer risk (long-term immunosuppression)Hypersensitivity reactionsRisk of reactivation of latent infections
06

Interacting drugs

Ustekinumab (targets IL-12/IL-23 p40)

1 more in the full profile.

07

Biomarkers

Elevated IL-12/IL-23 p40 levels in serum for monitoring inflammatory or autoimmune conditions

Beyond the preview

Go deeper on Interleukin-12 and Interleukin-23 p40 subunit (IL-12/IL-23 p40).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin-12 and Interleukin-23 p40 subunit (IL-12/IL-23 p40).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call